Arrowhead Research | ARWR - Net Income


Arrowhead Research reported $-23.75M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
Arrowhead Research USD -23.75M 151.49M Sep/2025
Incyte USD 424.17M 19.17M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025
Xencor USD -6.03M 24.8M Sep/2025